AUS
NZ
UK
CA
USA
IND
Highlights
- Nanosonics unveils trophon3 with faster disinfection and digital integration
- trophon2 Plus software upgrade brings advanced features to existing systems
- Launch extends across multiple regions; FDA review in progress
Nanosonics (ASX:NAN), a medical technology firm specialising in infection prevention, has introduced its latest innovation in ultrasound probe disinfection — trophon3. This advanced system enhances high-level disinfection (HLD) by significantly improving operational efficiency, offering a disinfection cycle that is over 40% faster than its predecessors. Alongside speed, the system now includes cutting-edge digital integration and compatibility with DICOM imaging databases, delivering robust traceability for healthcare providers.
In addition to this flagship product, the company has also announced trophon2 Plus, a software upgrade designed for existing users of trophon2 systems. This upgrade provides many of the same benefits seen in trophon3, such as streamlined workflows and enhanced digital capabilities, without requiring a complete system overhaul. This move is likely to help healthcare institutions maximise the utility of their current equipment while aligning with modern digital standards.
The product rollout has begun across Europe, the United Kingdom, Australia, and New Zealand, with strong market interest anticipated due to increasing focus on infection control practices in clinical environments. Notably, Nanosonics has filed an application with the United States Food and Drug Administration (FDA), which is currently under review — a key step for potential entry into the large U.S. healthcare market.
This launch underscores Nanosonics’ strategic focus on driving innovation while supporting its existing customer base. By offering both a new-generation system and an upgrade pathway, the company aims to maintain its leadership in the automated HLD space for ultrasound transducers.
As a member of the ASX 200, Nanosonics remains a notable player within the Australian healthcare technology landscape. The company’s continued investment in research and development, coupled with its commitment to delivering practical advancements in medical hygiene, positions it well for sustained global expansion.
With the combined launch of trophon3 and trophon2 Plus, Nanosonics is not only enhancing infection prevention technologies but also reinforcing its role in modernising healthcare workflows in an increasingly digitised world.
